The State Food and Drug Administration recently approved the use of the long-acting injection for the treatment of schizophrenia by Xi'an Janssen Pharmaceutical Co., Ltd., namely paliperidone palmitate, for the treatment of acute and maintenance of schizophrenia. Officially listed in China. For mental illnesses that account for more than 20% of the total burden of disease in our country, how to reduce the recurrence of mental illness and reduce the burden of mental illness has become a public health issue that the government and medical workers should attach great importance to.
Director of the Department of Mental Health Management of the Ministry of Health, Jun Yan pointed out that in the next 20 years, mental illness including schizophrenia will cause economic losses of 16 trillion U.S. dollars (about 100 trillion yuan), which will give the global economy Bring a considerable impact. Mental illness ranks first in the ranking of global disease burden in 2005. At that time, our mental illness accounted for about 20% of the total burden of the disease. It is expected that by 2020, this ratio will rise to 25%. How to effectively use existing resources and use drugs to prevent recurrence is the government and medical workers should pay high attention to public health issues.
Professor Jiang Kaida of the Shanghai Mental Health Center said: "In China, high recurrence is a major problem and challenge for the treatment of schizophrenia, and prevention of relapse has also become one of the main goals of treatment for schizophrenia. The reason for relapse is often the interruption of antipsychotics. According to a recent study of the recurrence of schizophrenia, the relapse rate in one year in patients with schizophrenia in China is 40.8%, and the relapse rate due to poor drug compliance is about 43%. It is easy to relapse, so that the social function continues to decline, and the new long-acting injection can ensure continuous treatment for patients to reduce the recurrence.In the field of psychiatric treatment, Sunstar is the only new long-acting injection that can be injected once a month in China. Approved for the prevention of relapse provides an innovative, more promising treatment options."
Professor Shi Tianmei from the No. 6 Hospital of Peking University also confirmed through clinical studies that the use of long-acting injections can not only effectively prevent recurrence, but also reduce the burden of daily medication and stigma, and help patients return to society. If you choose long-acting injections early in the course of the disease, you can get better symptoms and improve cognitive function.
The approval of this drug is based on the results of a non-inferiority design study of multicenter, randomized, and active drug control in China. In the 13-week clinical study, the final PANSS total score decreased by 23.6 points from the baseline in the Shansi group. Through the comparison of the PANSS total scores, it was confirmed that the efficacy of Shansi Da monotherapy in the acute phase of schizophrenia was not significant. Less than the first three weeks of long-acting risperidone injection microspheres combined with oral risperidone tablets. Both the study and foreign registration studies suggest that Shansi Da is currently the only long-acting anti-psychotic agent effective in the acute phase of monotherapy.
In another randomized, double-blind, placebo-controlled study of maintenance treatment of schizophrenia, the recurrence rate of sirostar (18% [n=36/205]) was significantly less than that of placebo (48% [ n=97/203]). The study suggests that Zenstar significantly reduces the risk of relapse during maintenance therapy.
"The efficacy and safety of Zensita have been confirmed. The drug has been approved for marketing to provide a more effective treatment for patients with schizophrenia." Professor Zhao Jingping, chairman of the Chinese Medical Association Psychiatric Branch, said: "High recurrence is schizophrenia. The main problems and challenges in the treatment of the disease are the continuous and effective treatment from the acute phase to the maintenance phase, which is the key to reduce the recurrence.Chen Sida is currently the only one that can effectively act in the acute phase and can effectively prevent relapse in the long-term maintenance treatment. New antipsychotics are injected once a month, so patients can expect better results if they are used as early as possible.â€
The listing of Sunstar has not only provided Chinese doctors with a revolutionary treatment plan, but also brought benefits to thousands of patients suffering from schizophrenia in China. At present, Shansida has entered more than 40 hospitals in more than 10 provinces and cities, including Beijing, Guangdong, Jiangsu, Sichuan, and Shaanxi, and will gradually enter Shanghai, Hubei, and Hunan in the second half of the year.
Director of the Department of Mental Health Management of the Ministry of Health, Jun Yan pointed out that in the next 20 years, mental illness including schizophrenia will cause economic losses of 16 trillion U.S. dollars (about 100 trillion yuan), which will give the global economy Bring a considerable impact. Mental illness ranks first in the ranking of global disease burden in 2005. At that time, our mental illness accounted for about 20% of the total burden of the disease. It is expected that by 2020, this ratio will rise to 25%. How to effectively use existing resources and use drugs to prevent recurrence is the government and medical workers should pay high attention to public health issues.
Professor Jiang Kaida of the Shanghai Mental Health Center said: "In China, high recurrence is a major problem and challenge for the treatment of schizophrenia, and prevention of relapse has also become one of the main goals of treatment for schizophrenia. The reason for relapse is often the interruption of antipsychotics. According to a recent study of the recurrence of schizophrenia, the relapse rate in one year in patients with schizophrenia in China is 40.8%, and the relapse rate due to poor drug compliance is about 43%. It is easy to relapse, so that the social function continues to decline, and the new long-acting injection can ensure continuous treatment for patients to reduce the recurrence.In the field of psychiatric treatment, Sunstar is the only new long-acting injection that can be injected once a month in China. Approved for the prevention of relapse provides an innovative, more promising treatment options."
Professor Shi Tianmei from the No. 6 Hospital of Peking University also confirmed through clinical studies that the use of long-acting injections can not only effectively prevent recurrence, but also reduce the burden of daily medication and stigma, and help patients return to society. If you choose long-acting injections early in the course of the disease, you can get better symptoms and improve cognitive function.
The approval of this drug is based on the results of a non-inferiority design study of multicenter, randomized, and active drug control in China. In the 13-week clinical study, the final PANSS total score decreased by 23.6 points from the baseline in the Shansi group. Through the comparison of the PANSS total scores, it was confirmed that the efficacy of Shansi Da monotherapy in the acute phase of schizophrenia was not significant. Less than the first three weeks of long-acting risperidone injection microspheres combined with oral risperidone tablets. Both the study and foreign registration studies suggest that Shansi Da is currently the only long-acting anti-psychotic agent effective in the acute phase of monotherapy.
In another randomized, double-blind, placebo-controlled study of maintenance treatment of schizophrenia, the recurrence rate of sirostar (18% [n=36/205]) was significantly less than that of placebo (48% [ n=97/203]). The study suggests that Zenstar significantly reduces the risk of relapse during maintenance therapy.
"The efficacy and safety of Zensita have been confirmed. The drug has been approved for marketing to provide a more effective treatment for patients with schizophrenia." Professor Zhao Jingping, chairman of the Chinese Medical Association Psychiatric Branch, said: "High recurrence is schizophrenia. The main problems and challenges in the treatment of the disease are the continuous and effective treatment from the acute phase to the maintenance phase, which is the key to reduce the recurrence.Chen Sida is currently the only one that can effectively act in the acute phase and can effectively prevent relapse in the long-term maintenance treatment. New antipsychotics are injected once a month, so patients can expect better results if they are used as early as possible.â€
The listing of Sunstar has not only provided Chinese doctors with a revolutionary treatment plan, but also brought benefits to thousands of patients suffering from schizophrenia in China. At present, Shansida has entered more than 40 hospitals in more than 10 provinces and cities, including Beijing, Guangdong, Jiangsu, Sichuan, and Shaanxi, and will gradually enter Shanghai, Hubei, and Hunan in the second half of the year.
Food & Feed additive,High Quality Food & Feed additive,Food & Feed additive Details, CN
Xi'an JCF Herb Technology Development Co., Ltd , https://www.jcfherb.com